This post was originally published on this site A Phase 1 clinical trial testing DRGT-45 — a new oral formulation of abiraterone acetate — in men with prostate cancer has dosed its first participant, the treatment’s developer, Druggability Technologies (DRGT), announced. Abiraterone acetate is a form of hormone therapy already approved for men with advanced,…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows
This post was originally published on this site A combination of Opdivo (nivolumab) and Avastin (bevacizumab) is safe and has strong clinical activity in women with relapsed ovarian cancer, especially among those whose tumors were sensitive to platinum-based chemotherapy, a Phase 2 clinical trial shows. The study, “Assessment of Combined Nivolumab and Bevacizumab in Relapsed…
CRISPR-edited T-cells Safely, Effectively Target Cancer Cells in Myeloma Patients, Early Phase 1 Data Suggests
This post was originally published on this site A new approach using genetically modified T-cells — via CRISPR-Cas9 gene editing technology — safely and effectively targets cancer cells in patients with advanced multiple myeloma, preliminary data from a U.S.-based Phase 1 study show. Despite their preliminary nature, researchers believe these findings raise hope that this…
CytomX Initiates Phase 2 Trial Testing CX-072, Yervoy Combo in Relapsed or Refractory Melanoma
This post was originally published on this site CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating people with relapsed or refractory melanoma. The investigational probody CX-072 and Yervoy, developed by Bristol-Myers Squibb, are two…
Fertility Clinics and Breast Cancer ‘Previvor’ Team Up to Raise Awareness About Genetic Risk of Disease
This post was originally published on this site For patients with gene mutations that increase their risk for diseases such as breast cancer, fertility and in vitro fertilization (IVF) center Shady Grove Fertility (SGF) is offering individualized testing to lower the risk of passing the mutation to their children. To educate patients about such interventions, as…
CA125 Blood Test May Help Alert GPs to Ovarian and Other Cancers, Research Shows
This post was originally published on this site Commonly used in primary healthcare, blood tests for CA125 may help diagnose ovarian cancer and other types of cancer, particularly in older individuals, new research suggests. The findings were described in two presentations at the recent 2019 National Cancer Research Institute (NCRI) Conference in Glasgow, UK. The…
sIL-2R More Sensitive than ACE at Identifying Possible Cases of Sarcoidosis, Study Finds
This post was originally published on this site The soluble interleukin 2 receptor (sIL-2R) is more sensitive and specific than the angiotensin-converting enzyme (ACE), one of the most common diagnostic biomarkers of sarcoidosis, at identifying people who might have the disease, a study found. The findings were reported in the study, “Sensitivity and specificity of…
Janssen Requests FDA Approval of Imbruvica-rituximab Combo for First-line Treatment of CLL/SLL
This post was originally published on this site Janssen is seeking approval from the U.S. Food and Drug Administration (FDA) for a combination of Imbruvica (ibrutinib) with rituximab to be used as a first-line treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The supplemental New Drug Application (sNDA) requesting Imbruvica’s…
2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show
This post was originally published on this site Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared with chemotherapy alone, according to interim data of a Phase 3 study. AstraZeneca’s Imfinzi and the investigational tremelimumab…
Men with BRCA2 Mutations Should Get Regular PSA Screening, Phase 3 Interim Data Suggest
This post was originally published on this site Prostate-specific antigen (PSA) testing — a controversial approach to detecting prostate cancer — spotted the cancer more often, at a younger age, and in more serious forms in men older than 40 who carry mutations in the BRCA2 gene than in non-carriers, interim data of a large…
Nektar Launches First-in-Human Trial Testing NKTR-255 in Myeloma, Non-Hodgkin’s Lymphoma
This post was originally published on this site Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are excited to launch the first-in-human clinical study of NKTR-255, which has shown promising and substantial anti-tumor activity in…
Blood Test May Identify Breast Cancer Years Before Symptoms Appear, Pilot Study Suggests
This post was originally published on this site A simple blood test – which measures antibodies against certain tumor proteins, or antigens — may identify breast cancer up to five years before clinical signs of cancer are evident, but more research is needed to improve the test’s accuracy, a pilot study reports. Screening for a…